<DOC>
	<DOCNO>NCT02713282</DOCNO>
	<brief_summary>The purpose study estimate proportion participant fulfil criterion symptomatic remission follow transition 12 month treatment flexible-dose paliperidone palmitate 3 month formulation ( PP3M ) participant schizophrenia previously adequately treated paliperidone palmitate 1 month formulation ( PP1M ) least 4 month .</brief_summary>
	<brief_title>A Study Transition Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized Paliperidone Palmitate 1-Month Formulation</brief_title>
	<detailed_description>This international , multicenter ( study conduct multiple site ) study design estimate remission rate assess treatment response , tolerability , pattern use Paliperidone Palmitate 3-Month Formulation ( PP3M ) diverse population participant schizophrenia . The study consist screen phase ( Day -7 Day 1 ) , 52-week , open-label , flexible-dose PP3M treatment phase follow safety assessment 3 month ( +/-14 day ) month 12 visit early discontinuation . Participants ' Safety monitor throughout study .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Meets Diagnostic Statistical Manual Mental Disorders 5th edition ( DSM5 ) criteria diagnosis schizophrenia Able read , understand , sign inform consent form ( ICF ) indicate understands purpose procedure require study willing participate study Willing able fill selfadministered questionnaire Willing able adhere prohibition restriction specify protocol A woman childbearing potential must negative urine pregnancy test Screening baseline A woman must agree donate egg ( ovum , oocytes ) purpose assist reproduction study 6 month receive last dose study drug His/her psychiatric diagnosis due direct pharmacological effect substance ( example , drug abuse medication ) general medical condition ( example , clinically notable hypothyroidism , organic brain disorder ) Experienced intolerable side effect treatment paliperidone palmitate 1month formulation ( PP1M ) Has know hypersensitivity paliperidone risperidone Has receive longacting injectable antipsychotic medication PP1M within last 4 month first injection study drug paliperidone palmitate 3month formulation ( PP3M ) Has receive clozapine last 3 month Screening visit Is consider imminent risk suicide , even clinical intervention Has serious unstable medical condition , include recent present clinically relevant laboratory abnormality Has history current symptom tardive dyskinesia neuroleptic malignant syndrome Is woman pregnant breastfeeding , plan become pregnant enrolled study within 6 month last dose PP3M Has participate investigational drug trial 30 day prior Screening visit currently enrol investigational study Has current DSM5 diagnosis dissociative disorder , bipolar disorder , major depressive disorder , schizoaffective disorder , autistic disorder , intellectual disability and/or meet DSM5 definition severe substance use disorder ( except nicotine caffeine ) within 6 month prior screen ; however , participant mild moderate substance use disorder , exception intravenous drug use , eligible enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>R092670</keyword>
	<keyword>Paliperidone Palmitate</keyword>
</DOC>